title: An update on TroVax for the treatment of progressive castration-resistant prostate cancer.
abstract: Prostate cancer is a common human malignancy with few effective therapeutic options for treating advanced castration-resistant disease. The potential therapeutic effectiveness of immunotherapy and vaccines, in particular, has gained popularity based on the identification of prostate-associated antigens, potent expression vectors for vaccination, and data from recent clinical trials. A modified vaccinia Ankara (MVA) virus expressing 5T4, a tumor-associated glycoprotein, has shown promise in preclinical studies and clinical trials in patients with colorectal and renal cell carcinoma. This review will discuss the rationale for immunotherapy in prostate cancer and describe preclinical and limited clinical data in prostate cancer for the MVA-5T4 (TroVax(®)) vaccine.
authors.affiliation: Department of Urology, Rush University Medical Center, Chicago, IL, USA;
authors.forename: Michael
authors.initials: M
authors.lastname: Abern
authors.forename: Howard L
authors.initials: HL
authors.lastname: Kaufman
authors.forename: Kalyan
authors.initials: K
authors.lastname: Latchamsetty